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Abstract 
BACKGROUND: Hepatocellularcarcinoma (HCC) metastasis include intrahepatic and extrahepatic metastasis. 
Similar to intrahepatic metastasis, extrahepatic metastases are not unusual in cases with HCC. However, colonic 
metastasis is infrequent. 
CASE REPORT: We describe a clinical case, he was diagnosed with HCC a year ago, treated with TACE 
(transarterialchemoembolisation), re-examined with abdominal pain and defecation disorder. The tests such as 
CT scan, colorectal endoscopy, fine needle aspiration (FNA) revealed secondary metastatic lesion of HCC in 
sigmoid colon. This is the first gastrointestinal (GI) tract metastatic we have encountered. 
CONCLUSION: HCC metastases of the colon are rare, especially cases of hematogenous spread. The prognosis 
of these patients is often very critical. Indications for surgical removal of the lesion may be used if the general 
situation of patient is acceptable. 
 
 
 
 
 
 
 
Introduction 
 
In the top ten frequent cancers worldwide, the 
cancers of lung, breast, prostate, colon, nonmelaoma 
of skin, and stomach are followed by primary liver 
cancer. On the other hand, primary liver cancer is one 
of most common causes of death which relative to 
cancer diseases globally due to its extremely poor 
prognosis [1]. It is not denying that many patients 
could not be diagnosed at early stage. Even though 
surveillance programs for early liver cancer and 
hepatocellular carcinoma (HCC) have been 
implemented. Consequently, only 30% of them take 
advantage of radical treatment such as hepatectomy, 
liver transplant surgery [2]. Extrahepatic metastasis of 
HCC is not rare, lung and adrenal are two of typical 
side. Gastrointestinal (GI) tract metastasis from HCC 
is not common. Distal colon metastasis is extremely 
uncommon situation of extrahepatic metastasis. This 
article aims to present a case of HCC patient with a 
single colonic metastatic lesion which derive from 
HCC treated with TACE. 
 
 
Case Report 
 
The patient was 60 years old; he had been 
infected hepatitis B virus for 15 years was determined 
to have HCC in 2018. He received TACE. This man 
has been reexamined every three months. The result 
of CT scans and AFP test were normal. He visited our 
center because tenesmus and left lower quadrant 
abdominal pain lasting for several days. 
Nothing abnormal was found during physical 
examination. The result of AFP was 9.48 ng/ml. Other 
laboratory tests were within normal limits. A 
colonoscopy revealed a mass located in sigmoid 
colon with intact overlying mucosa so the biopsy 
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procedure was not performed. CT scan revealed a 50 
x 60 mm sized, bulging contoured mass located in 
sigmoid colon (Figure 1E and 1F). A natural 
hypodense mass with 39 x 41 mm located in segment 
IV – VIII of liver (Figure 1A), no enhancement at 
arterial phase. Several hypervascular lesions located 
in both lobes (Figure 1B and 1C). An ultra sound – 
guided FNA biopsy was performed. Result of 
pathology demonstrated metastasis of carcinoma. 
 
Figure 1: CT scan result: A natural hypodense mass with 39 x 41 
mm located in segment IV – VIII  
 
At the multidisciplinary team meeting, we 
decided that he would undergo surgical treatmet first. 
The patient underwent anterior resection. He tolerated 
that surgical procedure without any complication. 
Gross examination, the 15 cm rectosigmoid 
segment with smooth surface mucosa had two well-
circumscribed masses measuring 50 x 40 x 35 mm 
and 15 x 10 x 10 mm and pushing the serosa. The cut 
surface was tan-yellow. Nine masses ranging from 15 
x 10 x 10 mm to 30 x 30 x 20 mm attaching to adipose 
tissue were removed from the mesentery. They 
shared similar features with intestinal masses. 
Histopathological examination showed the tumor 
found under the mucosa was composed of atypical 
polygonal cells with irregular hyperchromatic nuclei, 
prominent nucleoli and clear or eosinophic cytoplasm 
(Figure 2A). They were arranged in large sheets or 
trabeculae. Vascular invasion was seen (Figure 2B). 
 
Figure 2: The tumor is in submucosa, was composed of a typical 
polygonal cells that resemble HCC 2A) and vascular invasion 2B) 
 
Immunohistochemistry staining were utilized. 
They show the reacting positively for Hepar-1 and 
Arginase-1 (Figure 3A and B). 
 
Figure 3: Immunohistochemicalstaiing, the tumor cells were positive 
for Hepar-1 3A) and Arginase-1 3B) 
 
After completing recovery, he started received 
HAIC (hepatic arterial infusion chemotherapy). We 
concluded that the metastasis lesion in sigmoid colon 
appeared due to the seeding which occurs after some 
interventional techniques such as TACE. The lesion 
had been removed completely. On the other hand, 
there was no evidence of other extrahepatic 
metastasis. Moreover, the patient did not accept the 
expense of target therapy. As result, we decided HAIC 
is convenience therapy for him. The patient had been 
treated with HAIC-mFP, 3 cycles. The response was 
quite good. AFP and PIVKA-II were decrease. 
 
 
Discussion 
 
Currently, liver cancer is classified as the third 
cause of death due to malignant diseases over the 
world, approximately 800 000 per year. Liver cancer 
has particular age, sex and geographic distributions, 
likely influenced by certain etiologic variables. 
Histologically, the majority of liver cancer falls into one 
of two categories: HCC and ICC (intrahepatic 
cholangiocarcinoma), and cholangiocarcinoma is less 
common. Even though malignant hepatic tumor is 
more common in developing countries, it is still 
significantly prevalent in other developed regions such 
as North America and central Europe [3]. While other 
cancers, like breast, lung, and colorectal cancer are 
on the decline, the mortality rate for primary liver 
cancer has increased in both sexs in recent decades 
[4]. While hepatitis B is a paving hepatic cancer risk 
factor in Asia, hepatitis C infection is reason why the 
incidence of liver cancer is increasing in the US. 
Furthermore, other significant risk factors include 
aflatoxin B1 poisoning, diabetes, alcoholicabuse, non-
alcoholoc fatty liver disease [5]. 
Among malignant diseases of the liver, the 
most frequent is HCC, the direct cause of the disease 
is unclear, the mechanism of the disease is thought to 
be a disorder of the DNA structure of the cell nucleus 
[6]. According the Globocan 2018 data base, the 
number new HCC cases in Vietnam (both sexes, all 
ages) is highest (25 335 – 15.4%). As reported by a 
recently published study on HCC in southern and 
central Vietnam, statistics show that there were 24 
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091 patients between 2010 and 2016, with a 
significant increase over the years (from 2793 cases 
in in 2010 to 4069 in 2016), men were the majority 
compared to women, most patients were positive for 
viral hepatitis (88.3% positive for hepatitis B or 
hepatitis C and 2.7% simultaneously positive for both 
of them) [7]. 
HCC is considered to be a cancer with a very 
high degree of malignancy, it has the tend to invade 
the portal vein as well as the liver vein. Therefore, 
lymph node metastases and distant metastases are 
also common, about 50% [8], especially for tumors 
larger than 5 cm in diameter [9]. Most extrahepatic 
HCC has been observed in cases with advanced 
stage of disease (stage VIa), as expected [10]. The 
longer a patient survives, the more risk of extra-
hepatic metastases increases and metastases to the 
lungs, bones, lymph nodes are most common [8]. 
Signs and symptoms of patients suffering 
from HCC primarily focused on the manifestation of 
the primary tumor and the metastatic features later. 
Recently, the metastatic characteristics of HCC has 
displayed two alluring new behaviors: the unexpected 
spread site, and the discovery of the metastatic lesion 
before the primary tumor is recognized. Metastases to 
the gastrointestinal tract are rare and mainly reported 
by clinical case reports. Direct invasion through the 
adjoining serous tumor due to the excessive growth of 
a primary tumor is a common mechanism and the 
invasive organ is often the duodenum, the stomach, 
jejunum, and colon (anatomical location close to the 
liver) [11], [12]. Metastases to other parts of the 
gastrointestinal tract are rarer and have not been 
adequately explained. Hematogenous dissemination 
is a hypothesis of distant GI tract metastasis. The 
explanation of haematogenous spread has been 
supposed to be the blockage of portal vein come after 
the vascular was infiltrated. The existence of tumour 
thrombosis in the portal vein may lead to a reversal of 
flow, which likely acts as the medium of 
haematogenous metastasis of HCC to the GI tract 
[13]. Transarterial embolization (TAE) and TACE can 
also cause increased portal vein pressure to cause 
blood clots and reverse flow [12], enabling HCC to 
invade nearby organs such as the colon or other parts 
of the digestive tract. 
Main local symptoms of colon metastasis from 
HCC patient are blood in stool, changed defecation 
pattern, abdominal pain, very similar with primary 
colorectal cancer. Unfortunately, gastrointestinal 
endoscopy is easy to confuse metastatic damage of 
HCC with polyps, mucosal tumors or colorectal ulcers. 
Sometimes, it is really difficult to identify them through 
endoscopic examination and performed biopsy, 
especially the lesions which have intact overlying 
mucosal. Therefore, immunohistochemistry is 
considered an effective tool for the differential 
diagnosis between liver cancer and adenocarcinoma 
of the colorectal. Hepar-1, Arg-1, GPC-3, p-CEA, 
BSEP are some popular inmmunohostochemical 
markers which are available for establishing the 
diagnosis. As previously study, Hepar-1 and p-CEA 
are the two most widely used markers for high 
sensitivity and specificity [14], [15]. 
Some reports indicate GI metastasis usually 
could be dectected between 3 months to 8 years from 
the initial confirmation of HCC [11], [16], [17]. 
Nasuizaka et al., reported an average survival time of 
HCC patients with metastatic gastrointestinal tract 
was 7 months (1-59 months) and only 24.9% lived 
more than 1 year or more [10]. Another aspect for 
these patients is whether the treatment to eliminate 
extrahepatic metastatic lesions is effective, especially 
in the early cases with good liver function and no 
portal vein invasion [18]. Although there is too little 
evidence and insufficient data to prove the 
effectiveness of surgical treatment, especially for 
colon metastases in HCC patients, we believe that 
surgery removes this type of metastatic injury is 
especially necessary for patients with only a single 
metastatic lesion and good physical condition. 
In conclusion, this article aims to report a 
patient with HCC who has metastases of sigmoid 
colon. This is a very rare clinical morphology and is 
the first case in our clinic. Medical history has noted 
that HCC's extrahepatic metastases are quite 
common but colon metastases are very rare. Like 
other metastatic cases, colon metastasis patients 
have not delight outcome. Surgery to remove 
metastatic lesions is thought to be a treatment option 
especially for patients who had good liver function and 
acceptable condition. 
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